Compile Data Set for Download or QSAR
Report error Found 105 Enz. Inhib. hit(s) with all data for entry = 9142
TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(US10098883, Example 77 | 9-Fluoro-10-phenyl-4-(pip...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(US10098883, Example 79 | 10-Chloro-8-methyl-4-(pip...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(US10098883, Example 27 | 7-Bromo-4-(piperidin-4-yl...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309(US10098883, Example 52 | (−)-trans-10-Ethoxy...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(US10098883, Example 95 | 10-(2-Fluorophenyl)-4-(pi...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(US10098883, Example 63 | 10-Cyclopentyl-4-(piperid...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(US10098883, Example 67 | 4-(Piperidin-4-yl)-10-[2-...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307(US10098883, Example 50 | (−)-trans-10-Bromo-...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(US10098883, Example 55 | 4-(Piperidin-4-yl)-10-[4-...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(US10098883, Example 56 | 10-Phenyl-4-(piperidin-4-...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(US10098883, Example 60 | 10-Bromo-4-(piperidin-4-y...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(US10098883, Example 72 | 10-sec-Butyl-4-(piperidin...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290308(US10098883, Example 51 | (−)-trans-4-(2-Meth...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290311(US10098883, Example 54 | 10-(4-Methoxyphenyl)-4-(p...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290315(US10098883, Example 58 | 4-(Piperidin-4-yl)-10-(py...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290262(10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290328(US10098883, Example 71 | 10-Bromo-7-fluoro-4-(pipe...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290331(US10098883, Example 74 | 10-Bromo-9-methyl-4-(pipe...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290333(US10098883, Example 76 | 10-Isopropoxy-4-(piperidi...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290335(US10098883, Example 78 | 10-(2,6-Difluorophenyl)-4...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290343(US10098883, Example 86 | 10-(1-Methyl-1H-pyrazol-5...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290316(US10098883, Example 59 | 4-(Piperidin-4-yl)-10-(py...)
Affinity DataIC50: 16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290332(US10098883, Example 75 | 10-Bromo-7-methyl-4-(pipe...)
Affinity DataIC50: 16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290338(US10098883, Example 81 | 10-Bromo-8-fluoro-4-(pipe...)
Affinity DataIC50: 16nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290303(US10098883, Example 46 | 10-Phenyl-4-(piperidin-4-...)
Affinity DataIC50: 17nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290293(US10098883, Example 36 | 10-Methyl-4-(piperidin-4-...)
Affinity DataIC50: 18nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290319(US10098883, Example 62 | 10-Isopropyl-4-(piperidin...)
Affinity DataIC50: 18nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290337(US10098883, Example 80 | 4-(Piperidin-4-yl)-10-[2-...)
Affinity DataIC50: 18nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290342(US10098883, Example 85 | 10-(2-Methylphenyl)-4-(pi...)
Affinity DataIC50: 18nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(US10098883, Example 95 | 10-(2-Fluorophenyl)-4-(pi...)
Affinity DataIC50: 18nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290321(US10098883, Example 64 | 10-(2-Chlorophenyl)-4-(pi...)
Affinity DataIC50: 19nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290326(US10098883, Example 69 | 10-Chloro-9-methyl-4-(pip...)
Affinity DataIC50: 20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290339(US10098883, Example 82 | 4-(Piperidin-4-yl)-10-(py...)
Affinity DataIC50: 20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290284(US10098883, Example 25 | 3-Fluoro-7-(piperidin-4-y...)
Affinity DataIC50: 21nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(US10098883, Example 53 | 2-Oxo-4-(piperidin-4-yl)-...)
Affinity DataIC50: 21nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290276(US10098883, Example 17 | 3,4-Dimethyl-8-(piperidin...)
Affinity DataIC50: 22nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290279(US10098883, Example 20 | 10-Iodo-4-(piperidin-4-yl...)
Affinity DataIC50: 22nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290298(US10098883, Example 41 | 10-Chloro-4-(piperidin-4-...)
Affinity DataIC50: 23nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290330(US10098883, Example 73 | 10-Isobutyl-4-(piperidin-...)
Affinity DataIC50: 23nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290341(US10098883, Example 84 | 4-(Piperidin-4-yl)-10-(3-...)
Affinity DataIC50: 23nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290296(US10098883, Example 39 | 8-Chloro-4-(piperidin-4-y...)
Affinity DataIC50: 24nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290304(US10098883, Example 47 | 10-methyl-4-(piperidin-4-...)
Affinity DataIC50: 24nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290318(US10098883, Example 61 | 10-Cyclopropyl-4-(piperid...)
Affinity DataIC50: 24nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290347(US10098883, Example 90 | 10-Chloro-9-fluoro-4-(pip...)
Affinity DataIC50: 24nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290322(US10098883, Example 65 | 10-(2-Methoxyphenyl)-4-(p...)
Affinity DataIC50: 25nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290325(US10098883, Example 68 | (−)-trans-10-Chloro...)
Affinity DataIC50: 25nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290344(US10098883, Example 87 | 10-(1-Methyl-1H-pyrazol-4...)
Affinity DataIC50: 25nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290270(US10098883, Example 11 | 4-(Piperidin-4-yl)-8-(tri...)
Affinity DataIC50: 26nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

TargetPlasminogen [101-181](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290278(US10098883, Example 19 | 9-Bromo-4-(piperidin-4-yl...)
Affinity DataIC50: 26nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/15/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 105 total ) | Next | Last >>
Jump to: